XILIO THERAPEUTICS INC (XLO) Stock Income Statement
NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.27M | 6.34M | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 66.23M | 65.99M | 79.13M | 89.15M | 75.04M | |||
| Research and Development | 39.08M | 41.21M | 52.14M | 59.20M | 51.19M | |||
| Selling, General, and Administrative Expenses | 27.15M | 24.78M | 27.00M | 29.95M | 23.86M | |||
| Operating Income | -56.96M | -59.65M | -79.13M | -89.15M | -75.04M | |||
| Interest Income/Expense | N/A | -100.00K | -700.00K | -800.00K | -600.00K | |||
| Other Income/Expense | 2.64M | 2.44M | 3.43M | 1.73M | -160.00K | |||
| Non Recurring Items | 11.00K | -937.00K | N/A | N/A | N/A | |||
| Income Before Taxes | -54.30M | -58.24M | -76.40M | -88.22M | -75.80M | |||
| Net Income | -54.30M | -58.24M | -76.40M | -88.22M | -75.80M | |||
| EBITDA | -55.26M | -58.00M | -77.23M | -87.30M | -73.54M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.84 | -1.09 | -2.78 | -3.22 | -2.84 | |||
| Non GAAP EPS | -0.84 | -1.28 | -2.78 | -3.22 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -585.54% | -918.05% | N/A | N/A | N/A | |||
| Operating Profit Margin | -614.16% | -940.18% | N/A | N/A | N/A | |||
All data in USD